Current ratio spoločnosti Edesa Biotech
Aká je hodnota metriky Current ratio spoločnosti Edesa Biotech?
Hodnota metriky Current ratio spoločnosti Edesa Biotech, Inc. je 1.29
Aká je definícia metriky Current ratio?
Current ratio je ukazovateľ likvidity, ktorý meria či má spoločnosť dostatok zdrojov na splnenie svojich krátkodobých záväzkov.
The current ratio is an indication of a company's liquidity and measures the capability to meet a company's short-term obligations. It compares a firm's current assets to its current liabilities, and is expressed as current assets divided by current liabilities. The ratio is only useful when two companies are compared within industry because inter industry business operations differ substantially. To determine liquidity, the current ratio is not as helpful as the quick ratio, because it includes all those assets that may not be easily liquidated, like prepaid expenses and inventory.
Acceptable current ratios vary from industry to industry. In many cases an investor would consider a high current ratio to be better than a low current ratio, because a high current ratio indicates that the company is more likely to pay the investor back. Large current ratios are not always a good sign for investors. If the company's current ratio is too high it may indicate that the company is not efficiently using its current assets or its short-term financing facilities. If current liabilities exceed current assets the current ratio will be less than 1. A current ratio of less than 1 indicates that the company may have problems meeting its short-term obligations.
Some types of businesses can operate with a current ratio of less than one however. If inventory turns into cash much more rapidly than the accounts payable become due, then the firm's current ratio can comfortably remain less than one. Inventory is valued at the cost of acquiring it and the firm intends to sell the inventory for more than this cost. The sale will therefore generate substantially more cash than the value of inventory on the balance sheet. Low current ratios can also be justified for businesses that can collect cash from customers long before they need to pay their suppliers.
Current ratio spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Edesa Biotech
Čomu sa venuje spoločnosť Edesa Biotech?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Firmy s metrikou current ratio podobnou spoločnosti Edesa Biotech
- Hodnota metriky Current ratio spoločnosti Berger Paints India je 1.29
- Hodnota metriky Current ratio spoločnosti A2B Australia je 1.29
- Hodnota metriky Current ratio spoločnosti Realites SCA je 1.29
- Hodnota metriky Current ratio spoločnosti Nomura je 1.29
- Hodnota metriky Current ratio spoločnosti Shriram EPC je 1.29
- Hodnota metriky Current ratio spoločnosti Yunhong CTI Ltd je 1.29
- Hodnota metriky Current ratio spoločnosti Edesa Biotech je 1.29
- Hodnota metriky Current ratio spoločnosti Emcor je 1.29
- Hodnota metriky Current ratio spoločnosti Yip's Chemical je 1.29
- Hodnota metriky Current ratio spoločnosti MSP Steel & Power je 1.29
- Hodnota metriky Current ratio spoločnosti Trip Technologies je 1.29
- Hodnota metriky Current ratio spoločnosti Kajima je 1.29
- Hodnota metriky Current ratio spoločnosti National Fittings je 1.29